Although studies had shown the non-inferiority of albinterferon alfa-2b for chronic hepatitis C as compared to PEG-IFN alfa, its use on-market was prohibited by lung toxicities, e.g. fibrosing alveolitis, hemoptysis, bronchospasm or interstitial lung disease [9, 10]. The gene discussed is IFNA1; the disease is chronic hepatitis C virus infection.